A First-in-Human Single and Multiple Ascending Dose Study of MT-201
NCT07219368
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Volunteer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 19 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mirador Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- November 4, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Mirador Clinical Department, San Diego, California 92121 · San Diego, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.